FGFR2 and gastric cancer: Hence, there is significant interest in FGFR2 as a therapeutic target for FGFR2‐amplified gastric cancers, and preclinical and clinical evaluation of FGFR inhibitors are actively ongoing (Chang et al., 2015; Gozgit et al., 2012; Kim et al., 2014; Xie et al., 2013).